Volume 18, Issue 69 (4-2009)                   jour guilan uni med sci 2009, 18(69): 1-5 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Saeedi Saedi. H, Tavakoli Tabasi K, Mohammadian Roshan N, Shakeri M. Study of Her2/neu Protein over Expression Frequency and Its Relationship with Grade, Stage in Patients with Non Metatstatic Transitional Cell Carcinoma and Disease Free Survival. jour guilan uni med sci. 2009; 18 (69) :1-5
URL: http://journal.gums.ac.ir/article-1-260-en.html
Guilan University of Medical Sciences
Abstract:   (6818 Views)
Abstract Introduction: HER2 over-expression has been identified in a variety of malignant tumors including bladder transitional carcinoma. In some researches HER2 was detected in 10%-50% of muscle invasive bladder cancers. In this study we evaluated the correlation between HER2 over-expression and pathological characteristics as well as its impact on the disease free survival (DFS) of patients with non-metastatic bladder transitional carcinoma. Objective: Study of Her2/neu Protein over Expression Frequency and Its Relationship with Grade, Stage in Patients with Non Metatstatic Transitional Cell Carcinoma and Disease Free Survival Materials and Methods: In this retrospective cohort study, paraffin-embedded specimens from 50 patients with non-metastatic bladder transitional cell carcinoma, referred to Omid hospital from 2003 to 2007, were examined immunohistochemically for HER-2/neu over-expression. The specimens were also reviewed for tumor grade. The patients with superficial tumors underwent TURBT and a full course of intravesical BCG therapy and cases with muscle invasive tumor received cisplatin based chemoradiation. Results: There were 27 (54%) high grade and 23 low grade tumors. The specimens stained for HER-2 over-expression as follow: 11 as Zero, 11 as 1+, 13 as 2+ and 15 as 3+. The T stages of Tis, T1, T2 and T3 were detected in 14, 19, 10, and 7 cases respectively. The frequency of strong positive HER-2 tumors (3+) was significantly higher among patients with muscle invasive tumors compared to those with superficial lesions (58.8% vs. 15.2%, p<0.001). There was also a relatively significant association between strong positive HER-2 expression and high grade tumors (43.5% vs. 18.5% p= 0.055). The Median follow up time was 14 months (range, 4-52 months) during which 17 cases (34%) experienced recurrence (12 local, 3 bones & 2 lungs). For all patients 3-year DFS was 62.7% ± 7.4% which was significantly better for cases with superficial tumors than patients with muscle invasive tumors (78.1% vs. 19.5%, p=0.005). In patients with strong positive HER-2 expression tumors, DFS was significantly lower compared to the other cases (3-year DFS: 19.4% vs. 80%, p<0.001). No significant difference in DFS was found between high grade and low grade tumors (3-DFS: 53.9% vs. 70%, p=0.20). Conclusion: In This study, strong HER-2 over-expression (3+) was significantly associated with higher T stages as well as high grade tumors. In addition to T stage, strong HER-2 over-expression was a significant predictor of lower disease free survival.
Full-Text [PDF 156 kb]   (901 Downloads)    
Type of Study: Research | Subject: Special
Received: 2013/11/23 | Accepted: 2013/11/23 | Published: 2013/11/23

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2019 All Rights Reserved | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb